European Association for the Study of Diabetes--43rd Annual Meeting. Therapeutic approaches: Part 1. 18-21 September 2007, Amsterdam, the Netherlands.
Toft
Anders Dyhr
AD
Novo Nordisk A/S, Hummeltoftevej 49, DK-2830 Virum, Denmark. adto@novonordisk.com
D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D052216:Glucagon-Like Peptide 1 / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4